Jaguar Animal Health (JAGX)
(Delayed Data from NSDQ)
$3.81 USD
-0.12 (-2.93%)
Updated Jun 6, 2024 04:00 PM ET
After-Market: $3.76 -0.05 (-1.31%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Price, Consensus and EPS Surprise
JAGX 3.81 -0.12(-2.93%)
Will JAGX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for JAGX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for JAGX
Jaguar Animal Health, Inc. (JAGX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
JAGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for JAGX
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Jaguar Health executes out-license dal with JV Magdalena Biosciences
Jaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia
Jaguar Health anounces results of investigator-initiated trial of crofelemer
Investigator-Initiated Trial of Jaguar Health’s Crofelemer Yields Positive Results for Functional Diarrhea